This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.
Otherwise, you will be redirected to the institutional part of this website.
Thank you for your understanding.
The Latest From CureMatch
CureMatch will leverage mProbe’s targeted proteomics platform to assess individual proteins within patients’ tumor tissues. CureMatch, Inc., a healthcare technology company that leverages artificial intelligence (AI) to power precision medicine support for oncology, is proud to announce a collaboration with mProbe Inc., a premier CLIA-certified targeted proteomics company. mProbe utilizes a proprietary technology platform integrating […]
Oncologists will be able to submit claims to payers using a Category III CPT code, paving the way for wider adoption of precision treatment options. CureMatch, Inc., a leader in precision medicine support for oncology, is pleased to announce that the American Medical Association (AMA) has issued the new Current Procedural Terminology (CPT®) Category III […]
Congratulations to CureMatch CEO Navid Alipour for being named a Top Leader of Influence in Life Science Top 50 Honoree by San Diego Business Journal. Alipour is a long-time entrepreneur in the AI space, founding multiple companies with an emphasis on the convergence of AI and the life sciences – a model now referred to […]
Dr. Link, Dr. Shlain and Mr. Simon all bring deep entrepreneurial experience in the medical and pharmaceutical fields to precision medicine. SAN DIEGO, CA, UNITED STATES, July 21, 2022 /EINPresswire.com/ — CureMatch, Inc., a leader in precision medicine support for oncology, announced today that John S. Link, MD, Jordan Shlain, MD and Greg Simon have […]